As weight-loss drugs gain popularity globally, Nithin Kamath has raised questions about why India is not seeing the same level of enthusiasm for GLP-1 medications, even as prices become more affordable. His comments sparked a wider discussion after Biocon chief Kiran Mazumdar-Shaw weighed in, urging caution and emphasizing that diet and exercise should remain the first choice for people who are not clinically obese or diabetic.
ALSO READ: Weather tomorrow June 28